Genedata accelerating drug development
Genedata, a Basel IT company specializing in the life sciences sector, has agreed a collaboration with Thermo Fisher. The integration of their two platforms will help accelerate the development of drugs.
Genedata has developed a platform for managing data from biopharmaceutical research. This platform also allows data to be brought together from different sources and then processed. The announced collaboration with international pharmaceutical and laboratory equipment supplier Thermo Fisher will now enable the direct integration of Thermo Fisher’s robotics and automation platforms with the Genedata Biopharma Platform, as was reported in a Genedata press release.
The two companies will consequently be able to offer scientists a centralized platform that delivers automation systems for sample handling, lab operations and testing and enables them to digitally trace all results for every sample of imported raw instrument data. This will accelerate the discovery and development of next-generation biotherapeutics, the Basel IT company says. Integrating the two platforms gives researchers the power to make data-based decisions and uncover insights not possible before, explained Hansjoerg Hass, Senior Director Lab Automation at Thermo Fisher.
The integration includes both laboratory instruments and software from Thermo Fisher. Both companies are implementing interfaces for the seamless integration of all areas of the two platforms. Genedata has extensive experience in projects of this kind, with the Basel company’s IT solutions having been used by other major players to automate complex laboratory workflows with lab equipment, as Othmar Pfannes, CEO of Genedata, outlines.
Share this article
You may also be interested in
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More